RxDoctor Payments Data

John Lanza, MD

Otolaryngology · Port St Lucie, FLNPI 1932267663

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,000 of the $5,058 with a category attached, or 79.1%. 23 manufacturers reported payments, led by Intersect ENT, Inc. at 29.0% of the total. Reporting peaked in 2021 at $1,764 and has fallen 56.1% since, to $773 in 2025.

$5,058in general payments, 2019–2025

Across 128 payments — averaging $39.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intersect ENT, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$774
  • Sanofi$731
  • Stryker$438
  • Aerin Medical Inc.$331
  • Acclarent, Inc$207
  • plus $1K from 17 others
$111,894in research payments, 2019–2025

Across 33 payments — averaging $3390.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aerin Medical Inc.$62K
  • Neurent Medical Limited$50K

What the payments were for

  • Speaking & faculty fees$1,00020%
  • Food & beverage$4,00079%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,058 in reported general payments places this provider in the 80th percentile of 586 otolaryngology providers in Florida.

See all otolaryngology providers in Florida

Medicare billing

Part B allowed, 2024
$296,629
Medicare patients
628
Services billed
4,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$52,247
Dupixent SyringeDupilumab12$49,456
Epinephrine42$8,768
Ipratropium Bromide106$4,324
Fluticasone Propionate58$1,389
Azelastine Hcl42$1,173
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$1,017
Doxycycline Hyclate62$940
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort13$610
Omeprazole32$510
Azithromycin47$458
Mupirocin52$402
Penicillin V Potassium35$352
Clotrimazole16$351
Levothyroxine Sodium34$301

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →